NBIO 株価推移チャート
NBIO 収入
Nascent Biotech Inc
$0
0%
$0
終値： May 07, 16:00:00 GMT-4
$0
0%
$0
アフターマーケット：May 07, 20:00:00 GMT-4
戻る
Nascent Biotech Inc (NBIO) 収入
主要データ
前終値
$0.0002
始値
$0.0002
当日レンジ
$0.0002 - $0.0005
52週レンジ
$0.0001 - $0.1345
取引高
15.0K
平均取引高
52.2K
配当利回り
--
1株当たり利益(TTM)
-0.01
時価総額
$34.4K
NBIOとは何ですか？
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. The company is headquartered in North Palm Beach, Florida. The company went IPO on 2012-06-06. The firm focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The firm's lead candidate, Pritumumab (PTB), is a human monoclonal antibody (Mab) that has progressed to Phase 2 clinical trials for the treatment of Brain Cancer. Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer. Its other products include CLNH5 and MultiPharm. MultiPharm is a proprietary platform technology that may have additive and synergistic effects not only for cancer therapy but also for diabetes, autoimmunity, and transplantation.
